CG Oncology (CGON) Research & Development (2023 - 2026)
CG Oncology's (CGON) quarterly Research & Development came in at $43.7 million in Q1 2026, up 59.21% YoY from $27.5 million in Q1 2025, and up 45.97% on a QoQ basis from $30.0 million in Q4 2025.
CG Oncology (CGON) Research & Development (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Research & Development data on file, last reported at $43.7 million in Q1 2026.
- Quarterly Research & Development rose 59.21% year-over-year to $43.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.9 million (up 43.9% YoY) and the FY2025 annual result came in at $116.6 million, up 42.07% from the prior year.
- Research & Development rose to $43.7 million in Q1 2026, from $30.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $43.7 million in Q1 2026 to a low of $7.8 million in Q1 2023.
- A 4-year average of $22.2 million and a median of $19.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development surged 119.46% — and 2025, when it rose 11.78%.
- Tracing CGON's Research & Development over 4 years: stood at $16.3 million in 2023, then soared by 64.01% to $26.8 million in 2024, then increased by 11.78% to $30.0 million in 2025, then jumped by 45.97% to $43.7 million in 2026.
- The last three Research & Development figures came in at $43.7 million (Q1 2026), $30.0 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 54.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.66 Mn |
| Mar 31, 2026 | 43.73 Mn |
| Dec 31, 2025 | 29.96 Mn |
| Sep 30, 2025 | 27.88 Mn |
| Jun 30, 2025 | 31.33 Mn |
| Mar 31, 2025 | 27.47 Mn |
| Dec 31, 2024 | 26.80 Mn |
| Sep 30, 2024 | 19.62 Mn |
| Jun 30, 2024 | 18.47 Mn |
| Mar 31, 2024 | 17.21 Mn |
| Dec 31, 2023 | 16.34 Mn |
| Sep 30, 2023 | 11.74 Mn |
| Jun 30, 2023 | 9.83 Mn |
| Mar 31, 2023 | 7.84 Mn |